Reverse Transcriptase News and Research

RSS

U.S. scientists have successfully engineered blood vessels from human vascular cells in the lab

Tissue engineering has made considerable progress in the past decade, but advances have stopped short of clinical application for most tissues. For elderly patients tissue-engineered arteries could provide grafts for bypass surgery.

16 Jun 2005

Tentative approval for Lamivudine tablets

The U.S. Food and Drug Administration (FDA) has announced the tentative approval of Lamivudine Tablets manufactured by Aurobindo Pharma LTD. Hyderabad, India.

16 Jun 2005

Arteries bio-engineered from elderly cells

Researchers from Duke University's Medical Center and Pratt School of Engineering have demonstrated that they can grow new human blood vessels from cells taken from patients who especially need such assistance – older adults with cardiovascular disease.

14 Jun 2005

Bio-engineered skin provides clues to melanoma development

When it comes to the deadly skin cancer melanoma, studying functional tissue rather than cell lines may better provide insight into the disease's development, according to new research from a Howard Hughes Medical Institute predoctoral fellow at Stanford University School of Medicine.

12 Jun 2005

A drug used to prevent mother-to-child transmission of HIV-1 induces resistance more often than previously thought

The incidence of drug resistance associated with single-dose nevirapine, a drug used to prevent mother-to-child transmission of HIV-1, may be substantially higher than previously thought and of particular risk for those infected with HIV-1 subtype C, according to three new studies published in the July 1 issue of The Journal of Infectious Diseases, now available online.

1 Jun 2005

Telomerase finding has major implications for cancer

UCLA biochemists have determined the three-dimensional structure of a major domain of telomerase, the enzyme that helps maintain telomeres - small pieces of DNA on the ends of chromosomes that act as protective caps - allowing DNA ends to be copied completely when cells are replicated.

9 Mar 2005

New study following 12,574 individuals over the course of three years of HAART

Although clinical progression to AIDS of patients infected with Human immunodeficiency virus (HIV) has declined since the introduction of Highly Active Antiretroviral Therapy (HAART), there is little data on the changes in incidence of AIDS-defining events during the first few years of therapy.

28 Feb 2005

New compounds for the treatment of HIV/AIDS

Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.

27 Feb 2005

Blips and AIDS therapy

Researchers at Johns Hopkins have concluded that sudden, temporary spikes in the amount of HIV in the body, commonly called blips, do not always mean the virus is developing resistance to AIDS drugs.

14 Feb 2005

New 3-DCR HIV strain does not respond to three classes of anti-retroviral medication

A highly resistant strain of rapidly progressive human immunodeficiency virus (HIV) has been diagnosed for the first time in a New York City resident who had not previously undergone antiviral drug treatment, according to the Department of Health and Mental Hygiene (DOHMH).

13 Feb 2005

Finding points towards the possibility of retrovirus involvement in ALS (amyotrophic lateral sclerosis)

A significant proportion of patients suffering from ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig's disease or motor neuron disease, have a marker of retrovirus activity in their blood, reports the February 8 issue of the medical journal Neurology.

7 Feb 2005

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004

Protease inhibitors used to treat HIV-1 infection may also be effective for treatment or prevention of malaria

The study found protease inhibitors inhibited the growth of P. falciparum, the malaria parasite that causes most disease. These findings may also expose a previously unexplored vulnerability in the parasite that could lead to a new class of anti-malarial drug.

8 Nov 2004

Cellular enzyme represents a potential new target for developing improved HIV drugs

Scientists have discovered that a cellular enzyme helps ferry HIV genetic instructions out of the cell nucleus where they can then be translated into proteins to begin their most destructive work.

1 Nov 2004

One group of drugs that is effective in fighting HIV may also be promoting the death of sensory nerves in the skin

One group of drugs that is effective in fighting HIV may, paradoxically, also be promoting the death of sensory nerves in the skin, according to a study presented October 5, 2004, at the 129th annual meeting of the American Neurological Association in Toronto.

5 Oct 2004

Generic tritherapy can be used as a basic treatment for AIDS

A clinical trial, conducted in Cameroon by IRD researchers working with other organizations and supported by the ANRS, has demonstrated that one of the most common combinations currently deployed in Africa, using nevirapine, stavudine and lamivudine, satisfies these criteria.

5 Sep 2004

Reverse Transcriptase News and Research

U.S. scientists have successfully engineered blood vessels from human vascular cells in the lab

Tentative approval for Lamivudine tablets

Arteries bio-engineered from elderly cells

Bio-engineered skin provides clues to melanoma development

A drug used to prevent mother-to-child transmission of HIV-1 induces resistance more often than previously thought

Telomerase finding has major implications for cancer

New study following 12,574 individuals over the course of three years of HAART

New compounds for the treatment of HIV/AIDS

Blips and AIDS therapy

New 3-DCR HIV strain does not respond to three classes of anti-retroviral medication

Finding points towards the possibility of retrovirus involvement in ALS (amyotrophic lateral sclerosis)

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Protease inhibitors used to treat HIV-1 infection may also be effective for treatment or prevention of malaria

Cellular enzyme represents a potential new target for developing improved HIV drugs

One group of drugs that is effective in fighting HIV may also be promoting the death of sensory nerves in the skin

Generic tritherapy can be used as a basic treatment for AIDS

FDA reinforces use of Sustiva in first-line HIV combination therapy

First whole-genome survey of where three commonly used retroviruses into human DNA

Approval of fixed-dose combination treatments for HIV-1 infection

FDA approves two fixed-dose combination treatments for HIV-1 infection

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News